CA2313049A1 - . inhibition de la cyclooxygenase-2 - Google Patents

. inhibition de la cyclooxygenase-2 Download PDF

Info

Publication number
CA2313049A1
CA2313049A1 CA002313049A CA2313049A CA2313049A1 CA 2313049 A1 CA2313049 A1 CA 2313049A1 CA 002313049 A CA002313049 A CA 002313049A CA 2313049 A CA2313049 A CA 2313049A CA 2313049 A1 CA2313049 A1 CA 2313049A1
Authority
CA
Canada
Prior art keywords
cyclooxygenase
phenyl
methylsulfonyl
benzenesulfonamide
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002313049A
Other languages
English (en)
Inventor
Andrew J. Dannenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2313049A1 publication Critical patent/CA2313049A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

On utilise des inhibiteurs sélectifs de cyclooxygénase-2 pour traiter des hépatopathies et en combinaison avec des médicaments antiviraux afin de traiter des troubles hépatiques d'origine virale. Les inhibiteurs sélectifs de cyclooxygénase-2 inhibant également la synthèse de la cyclooxygénase-2, améliorent l'efficacité d'inhibiteurs sélectifs classiques de cyclooxygénase-2 dans le traitement d'états inflammatoires, de la maladie d'Alzheimer et du cancer.
CA002313049A 1997-12-17 1998-12-07 . inhibition de la cyclooxygenase-2 Abandoned CA2313049A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6995597P 1997-12-17 1997-12-17
US60/069,955 1997-12-17
PCT/US1998/025206 WO1999030721A1 (fr) 1997-12-17 1998-12-07 . inhibition de la cyclooxygenase-2

Publications (1)

Publication Number Publication Date
CA2313049A1 true CA2313049A1 (fr) 1999-06-24

Family

ID=22092236

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002313049A Abandoned CA2313049A1 (fr) 1997-12-17 1998-12-07 . inhibition de la cyclooxygenase-2

Country Status (4)

Country Link
EP (1) EP1039914A4 (fr)
AU (1) AU1703799A (fr)
CA (1) CA2313049A1 (fr)
WO (1) WO1999030721A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE425749T1 (de) * 1999-01-27 2009-04-15 Cornell Res Foundation Inc Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
CA2373879A1 (fr) * 1999-07-02 2001-01-11 Universitair Medisch Centrum Utrecht Therapie antivirale
EP1064940A1 (fr) * 1999-07-02 2001-01-03 Universitair Medisch Centrum Utrecht Thérapie antivirale
US6787573B2 (en) 1999-07-02 2004-09-07 Universiteit Utrecht Antiviral therapy
CA2403358A1 (fr) * 2000-03-17 2001-09-20 Universiteit Utrecht Therapie antivirale
KR20040072720A (ko) * 2002-01-10 2004-08-18 파마시아 앤드 업존 캄파니 항바이러스제와 함께 사용되는 유두종 바이러스 감염의치료를 위한 ｃｏｘ-2 억제제의 용도
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996039144A1 (fr) * 1995-06-06 1996-12-12 Procyte Corporation Complexes cuivreux stables utilises comme substances a activite therapeutique
ATE296114T1 (de) * 1996-02-13 2005-06-15 Searle & Co Zubereitungen, enthaltend einen cyclooxygenase-2- inhibitor und einen leukotrien-b4-rezeptor- antagonisten
DK0888127T3 (da) * 1996-02-13 2002-04-08 Searle & Co Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer

Also Published As

Publication number Publication date
EP1039914A1 (fr) 2000-10-04
AU1703799A (en) 1999-07-05
EP1039914A4 (fr) 2007-06-27
WO1999030721A1 (fr) 1999-06-24

Similar Documents

Publication Publication Date Title
RU2223116C2 (ru) Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
US6403630B1 (en) Treating cancers associated with overexpression of HER-2/neu
JPH10503211A (ja) 炎症の処置のための１，２−置換イミダゾリル化合物
US6803380B1 (en) 5-aryl-1h-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
CA2313049A1 (fr) . inhibition de la cyclooxygenase-2
WO2005048942A2 (fr) Polytherapie contenant un inhibiteur cox-2 et un agent antineoplasique
EA003603B1 (ru) N-[(замещенное пятичленное ди- или триазадиненасыщенное кольцо) карбонил] гуанидиновые производные для лечения ишемии
WO2003059271A2 (fr) Compositions et procedes de traitement comprenant des agonistes gamma du recepteur active du proliferateur du peroxysome et des inhibiteurs selectifs de la cyclooxygenase 2.
RU2001106644A (ru) Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p
CZ303101B6 (cs) Prípravek podporující tvorbu/sekreci neurotropinu
EP1109553A1 (fr) Traitement des maladies inflammatoires de la tete et du cou par des inhibiteurs de cyclooxygenase-2
IE81569B1 (en) Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids
JP3370347B2 (ja) 心臓および血管の肥大および過形成の治療剤
JPH11228410A (ja) イミダゾールアンジオテンシン−ｉｉ受容体拮抗薬からなる慢性腎不全治療剤
US6589997B2 (en) Small-molecule modulators of hepatocyte growth factor/scatter factor activities
RU2332996C2 (ru) Производные гидразонпиразола и их применение в качестве лекарственного средства
EP1682143A2 (fr) Association de l&#39;inhibiteur de hsp90 et de l&#39;inhibiteur de la phophodiesterase destinee a traiter ou prevenir la neoplasie
FR2642759A1 (fr) Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante
JP2005519878A5 (fr)
CA2494345A1 (fr) Combinaison d&#39;un inhibiteur de l&#39;aromatase et d&#39;un biphosphonate
US7041694B1 (en) Cyclooxygenase-2 inhibition
CA2471713A1 (fr) Derives de benzothiazole- et benzoxazole-4,7-diones et leur utilisation comme inhibiteurs de phosphatases
EP2624830A2 (fr) Procédés d&#39;utilisation de modulateurs à petite molécule de l&#39;activité du facteur de croissance (facteur de dispersion) de cellules hépatiques
RU2005109164A (ru) Производные 2-пирролидин-2-ил-[1, 3, 4]оксадиазола и их применение в качестве антидепрессантов
AU758983B2 (en) Use of a COX-2 inhibitor and a NK-1 receptor antagonist for treating inflammation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued